Web Desc
Lymphocytes and their Roles in Cancer
joint with Emerging Cellular Therapies: T Cells and Beyond
Organizer(s): Iannis Aifantis, Ugur Sahin and Mikala Egeblad
Date: February 11 - 15, 2018
Location: Keystone Resort, Keystone, CO, USA
Sponsored by Amgen Inc., BioLegend, Inc. and Incyte Corporation
For important information on the coronavirus, please click here
Summary of Meeting:
Leverage of the body’s own immune system is revolutionizing the way that we treat cancer as it can lead to dramatic and durable responses. Such anti-tumor therapies include reactivation of anti-tumor T cells, expansion of tumor-infiltrating lymphocytes (TILs), Chimeric antigen receptor (CAR) T cells and a variety of cancer vaccines. The focus or target of most these approaches are cells of the lymphocytic lineage (T, B, NK, dendritic cells), key components of both adaptive and innate immune response. At the same time, lymphocytes can also be malignant, as in the case of a large number of lymphocytic leukemia and lymphoma subtypes, and active components of the immune microenvironment, controlling tumor growth and anti-tumor response. This conference for the first time brings together scientists from these different areas of lymphocyte biology and provides an overview of lymphocyte development, transformation, terminal differentiation, location within the tumor microenvironment and anti-tumor activity. The conference also provides an update on novel therapy protocols that attempt to harness the function of lymphocytes against cancer and state-of-the-art technologies, including imaging and DNA/RNA sequencing approaches, that will help us visualize and molecularly dissect anti-tumor responses in experimental systems and cancer patients.
Scholarship Deadline: October 11 2017
Discounted Abstract Deadline: October 11 2017
Abstract Deadline: December 13 2017
Discounted Registration Deadline: December 13 2017
Abstract submission is now closed. Registered attendees may bring a poster onsite. Please contact our office at +1 800-253-0685; +1 970-262-1230 or email info@keystonesymposia.org if you are interested.


Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:

Amgen Inc.
BioLegend, Inc.Incyte Corporation
We gratefully acknowledge additional support for this conference from:
American Association for Cancer Research (AACR)Bethyl Laboratories, Inc.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Sunday, February 11 | 4:00PM - 8:00PM
Arrival and Registration
Room: Longs Peak Foyer


Sunday, February 11 | 6:00PM - 8:00PM
Welcome Mixer
Room: Longs Peak Foyer
No registration fees are used to fund alcohol served at this function.

Monday, February 12 | 7:00AM - 8:00AM
Breakfast
Room: Colorado Rockies Ballroom


Monday, February 12 | 8:00AM - 9:00AM
Welcome and Keynote Address
Room: Quandary Peak

Speaker 1 of 2
* Iannis Aifantis, New York University School of Medicine, USA

Monday, February 12 | 8:00AM - 9:00AM
Welcome and Keynote Address
Room: Quandary Peak

Speaker 2 of 2
Alexander Y. Rudensky, HHMI/Memorial Sloan Kettering Cancer Center, USA
Regulatory T Cells and their Functions in the Tumor Microenvironment

Monday, February 12 | 9:00AM - 11:15AM
Understanding Lymphocytic Malignancy: Leukemia and Lymphoma
Room: Quandary Peak

Speaker 1 of 6
* Adolfo Ferrando, Columbia University, USA

Monday, February 12 | 9:00AM - 11:15AM
Understanding Lymphocytic Malignancy: Leukemia and Lymphoma
Room: Quandary Peak

Speaker 2 of 6
Louis M. Staudt, NCI, National Institutes of Health, USA
The MYD88-TLR9-B Cell Receptor Complex as a Target for Therapy in Aggressive Lymphomas


Monday, February 12 | 9:00AM - 11:15AM
Understanding Lymphocytic Malignancy: Leukemia and Lymphoma
Room: Quandary Peak


Coffee Break

Monday, February 12 | 9:00AM - 11:15AM
Understanding Lymphocytic Malignancy: Leukemia and Lymphoma
Room: Quandary Peak

Speaker 4 of 6
Charles G. Mullighan, St. Jude Children's Research Hospital, USA
The Role of CREBBP Mutations in Drug Resistance in Acute Lymphoblastic Leukemia

Monday, February 12 | 9:00AM - 11:15AM
Understanding Lymphocytic Malignancy: Leukemia and Lymphoma
Room: Quandary Peak

Speaker 5 of 6
Katia Georgopoulos, Massachusetts General Hospital, USA
Super-Enhancer Circuits in B Cell Development and Transformation

Monday, February 12 | 9:00AM - 11:15AM
Understanding Lymphocytic Malignancy: Leukemia and Lymphoma
Room: Quandary Peak

Speaker 6 of 6
Anastasia N. Tikhonova, New York University Medical School, USA
Short Talk: Single-Cell Dynamics of Bone Marrow Microenvironment

Monday, February 12 | 9:00AM - 11:30AM
CAR/TCR Preclinical
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 1 of 7
* Carl H. June, University of Pennsylvania, USA


Monday, February 12 | 9:00AM - 11:30AM
CAR/TCR Preclinical
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 2 of 7
Philip D. Greenberg, University of Washington, USA
Making TCR-Modified T Cells Effective for Leukemia and Solid Tumors


Monday, February 12 | 9:00AM - 11:30AM
CAR/TCR Preclinical
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak


Coffee Break


Monday, February 12 | 9:00AM - 11:30AM
CAR/TCR Preclinical
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 4 of 7
Crystal L. Mackall, Stanford University, USA
What’s Next? Preclinical Studies Paving the Way for Future CAR T Cell Trials


Monday, February 12 | 9:00AM - 11:30AM
CAR/TCR Preclinical
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 5 of 7
Stanley R. Riddell, Fred Hutchinson Cancer Research Center, University of Washington, USA
Strategies to Improve the Efficacy of CAR T Cells in Solid Tumors


Monday, February 12 | 9:00AM - 11:30AM
CAR/TCR Preclinical
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 6 of 7
Reno Debets, Erasmus MC Cancer Institute, Netherlands
Short Talk: T Cell Receptors Equipped with ICOS Enhance T Cell Persistence and Mediate Sustainable Anti-Tumor Responses upon Adoptive T Cell Therapy


Monday, February 12 | 9:00AM - 11:30AM
CAR/TCR Preclinical
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 7 of 7
James Scott-Browne, La Jolla Institute, USA
Short Talk: Transcriptional Control of CAR-T Cell Function in Solid Tumors


Monday, February 12 | 11:15AM - 5:00PM
On Own for Lunch


Monday, February 12 | 11:15AM - 1:00PM
Poster Setup
Room: Colorado Rockies Ballroom


Monday, February 12 | 1:00PM - 10:00PM
Poster Viewing
Room: Colorado Rockies Ballroom


Monday, February 12 | 2:30PM - 4:30PM
Workshop 1: Understanding and Targeting Lymphocytes in Cance
r
Room: Quandary Peak

Speaker 1 of 9
* Iannis Aifantis, New York University School of Medicine, USA

Monday, February 12 | 2:30PM - 4:30PM
Workshop 1: Understanding and Targeting Lymphocytes in Cance
r
Room: Quandary Peak

Speaker 2 of 9
Eirini Giannakopoulou, Radiumhospitalet, Norway
T Cell Receptor-Mediated Targeting of Recurrent Neoantigens in Acute Myeloid Leukemia

Monday, February 12 | 2:30PM - 4:30PM
Workshop 1: Understanding and Targeting Lymphocytes in Cance
r
Room: Quandary Peak

Speaker 3 of 9
Wenting Zheng, St. Jude Children Research Hospital, USA
PI3K Orchestration of the in vivo Persistence of Chimeric Antigen Receptor-Modified T Cells

Monday, February 12 | 2:30PM - 4:30PM
Workshop 1: Understanding and Targeting Lymphocytes in Cance
r
Room: Quandary Peak

Speaker 4 of 9
Elena Montauti, Northwestern University, USA
USP22 Maintains Regulatory T Cells by Stabilizing Foxp3 Protein Level and Impairs Anti-Tumor Immune Response

Monday, February 12 | 2:30PM - 4:30PM
Workshop 1: Understanding and Targeting Lymphocytes in Cance
r
Room: Quandary Peak

Speaker 5 of 9
Jeffrey Ward, Washington University School of Medicine, USA
Remodeling of Myeloid as well as Lymphoid Compartments following Checkpoint Blockade Immunotherapy

Monday, February 12 | 2:30PM - 4:30PM
Workshop 1: Understanding and Targeting Lymphocytes in Cance
r
Room: Quandary Peak

Speaker 6 of 9
Soki Kashima, Kyoto University, Japan
WT1-Specific Cytotoxic T Lymphocytes Regenerated from T Cell-Derived iPS Cells Exert Therapeutic Effect in Xenograft Model of Renal Cell Carcinoma

Monday, February 12 | 2:30PM - 4:30PM
Workshop 1: Understanding and Targeting Lymphocytes in Cance
r
Room: Quandary Peak

Speaker 7 of 9
Chris Nicolai, University of California, Berkeley, USA
Mechanisms of MHC-Deficient Tumor Clearance using STING Agonists

Monday, February 12 | 2:30PM - 4:30PM
Workshop 1: Understanding and Targeting Lymphocytes in Cance
r
Room: Quandary Peak

Speaker 8 of 9
Julie Rytlewski, Bristol-Myers Squibb, USA
History of Prior Immunotherapy Changes Relationship between Tumor Mutations and TIL Repertoire

Monday, February 12 | 2:30PM - 4:30PM
Workshop 1: Understanding and Targeting Lymphocytes in Cance
r
Room: Quandary Peak

Speaker 9 of 9
Angela Vasaturo, INSERM, UMRS 1138, France
Unraveling the Immune Contexture of Pre-Invasive Lesions of the Lung by Multispectral Imaging

Monday, February 12 | 2:30PM - 4:30PM
Workshop 1: Perspectives from Industry
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 1 of 9
* Charles Sentman, Geisel School of Medicine at Dartmouth, USA


Monday, February 12 | 2:30PM - 4:30PM
Workshop 1: Perspectives from Industry
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 2 of 9
Amy Gilbert, Cell Design Labs, USA
Development of a SynNotch Combinatorial “and” Gate CAR T for Solid Tumors


Monday, February 12 | 2:30PM - 4:30PM
Workshop 1: Perspectives from Industry
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 3 of 9
Ian R. Hardy, TCR2 Therapeutics, USA
Improving CAR-T Cell Function with Small Molecule Treatment during Production


Monday, February 12 | 2:30PM - 4:30PM
Workshop 1: Perspectives from Industry
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 4 of 9
Kelan Hlavaty, SQZ Biotech, USA
Engineering T Cells Using a Microfluidic Intracellular Delivery Method for Cell Therapy


Monday, February 12 | 2:30PM - 4:30PM
Workshop 1: Perspectives from Industry
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 5 of 9
Robert J. Hofmeister, TCR2 Therapeutics, USA
A Novel T Cell Therapy Engaging the Complete T Cell Receptor


Monday, February 12 | 2:30PM - 4:30PM
Workshop 1: Perspectives from Industry
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 6 of 9
Lenka V. Hurton, ZIOPHARM Oncology, USA
Rapid Production of T Cells Co-expressing CAR and Membrane-bound IL-15 Potentiates Antitumor Activity and Promotes in vivo Memory


Monday, February 12 | 2:30PM - 4:30PM
Workshop 1: Perspectives from Industry
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 7 of 9
Sumiti Jain, Sangamo Therapeutics, USA
Precise T Cell Engineering using Enhanced Zinc-finger Nucleases (ZFNs) for Highly Specific and Efficient Dual Knock-Out of Endogenous T-Cell Receptor and HLA-Class I with Site-Specific Insertion of a CD19-CAR: Implications for Allogeneic T Cell Therapy


Monday, February 12 | 2:30PM - 4:30PM
Workshop 1: Perspectives from Industry
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 8 of 9
Inez Johanna, University Medical Center Utrecht, Netherlands
Towards the Next Generation CAR T Cells with TEGs: In vivo Efficacy – Toxicity Profile in Xenografts of Primary Human AML Disease and Healthy Bone Marrow


Monday, February 12 | 2:30PM - 4:30PM
Workshop 1: Perspectives from Industry
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 9 of 9
Levi Rupp, Cell Design Labs, USA
THROTTLETM CARs: A Novel Platform for Enhanced Safety and Efficacy via Titratable Control of CAR-T Activity using an FDA-Approved Small Molecule


Monday, February 12 | 4:30PM - 5:00PM
Coffee Available
Room: Longs Peak Foyer


Monday, February 12 | 5:00PM - 7:00PM
Therapeutic Targeting of Lymphocytic Malignancy
Room: Quandary Peak

Speaker 1 of 5
* Charles G. Mullighan, St. Jude Children's Research Hospital, USA

Monday, February 12 | 5:00PM - 7:00PM
Therapeutic Targeting of Lymphocytic Malignancy
Room: Quandary Peak

Speaker 2 of 5
Adolfo Ferrando, Columbia University, USA
Epigenetic Mechanisms in T-Cell Acute Lymphoblastic Leukemia

Monday, February 12 | 5:00PM - 7:00PM
Therapeutic Targeting of Lymphocytic Malignancy
Room: Quandary Peak

Speaker 3 of 5
Iannis Aifantis, New York University School of Medicine, USA
Targeting Stress Responses in Acute Lymphocytic Leukemia

Monday, February 12 | 5:00PM - 7:00PM
Therapeutic Targeting of Lymphocytic Malignancy
Room: Quandary Peak

Speaker 4 of 5
Andrei Thomas-Tikhonenko, Children's Hospital of Philadelphia and University of Pennsylvania, USA
Escape Hatches for Immunotherapies Targeting B-Cell Differentiation Antigens

Monday, February 12 | 5:00PM - 7:00PM
Therapeutic Targeting of Lymphocytic Malignancy
Room: Quandary Peak

Speaker 5 of 5
Jacques G. M. Ghysdael, Institut Curie, France
Short Talk: Triggering the Tcr Developmental Checkpoint Activates a Therapeutically Targetable Anti-Leukemic Pathway in T-Cell Acute Lymphoblastic Leukemia

Monday, February 12 | 5:00PM - 7:00PM
Synthetic Biology
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 1 of 5
* Crystal L. Mackall, Stanford University, USA


Monday, February 12 | 5:00PM - 7:00PM
Synthetic Biology
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 2 of 5
Darrell J. Irvine, Massachusetts Institute of Technology, USA
Chemically Engineering T Cell Therapies


Monday, February 12 | 5:00PM - 7:00PM
Synthetic Biology
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 3 of 5
Wendell A. Lim, University of California, San Francisco, USA
Optimizing Synthetic Biology Tools for T Cell Therapies


Monday, February 12 | 5:00PM - 7:00PM
Synthetic Biology
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 4 of 5
Travis Young, California Institute for Biomedical Research, USA
Controllable CAR-T Cell Therapy


Monday, February 12 | 5:00PM - 7:00PM
Synthetic Biology
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 5 of 5
Patrick Ho, University of California, Los Angeles, USA
Short Talk: COVERT T Cells: Engineering T Cells to Interrogate Intracellular Antigens


Monday, February 12 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Colorado Rockies Ballroom
No registration fees are used to fund alcohol served at this function.

Monday, February 12 | 7:30PM - 10:00PM
Poster Session 1
Room: Colorado Rockies Ballroom


Tuesday, February 13 | 7:00AM - 8:00AM
Breakfast
Room: Colorado Rockies Ballroom


Tuesday, February 13 | 8:00AM - 11:00AM
Cellular Therapies in Blood Malignancies and Beyond
Room: Quandary Peak

Speaker 1 of 7
* Ugur Sahin, BioNTech AG, Germany

Tuesday, February 13 | 8:00AM - 11:00AM
Cellular Therapies in Blood Malignancies and Beyond
Room: Quandary Peak

Speaker 2 of 7
Carl H. June, University of Pennsylvania, USA
CAR T Cells and their Therapeutic Promise in the Treatment of Leukemia

Tuesday, February 13 | 8:00AM - 11:00AM
Cellular Therapies in Blood Malignancies and Beyond
Room: Quandary Peak

Speaker 3 of 7
Crystal L. Mackall, Stanford University, USA
CAR Vulnerabilities: Emerging Insights from Clinical Trials

Tuesday, February 13 | 8:00AM - 11:00AM
Cellular Therapies in Blood Malignancies and Beyond
Room: Quandary Peak


Coffee Break

Tuesday, February 13 | 8:00AM - 11:00AM
Cellular Therapies in Blood Malignancies and Beyond
Room: Quandary Peak

Speaker 5 of 7
Chiara Bonini, Ospedale San Raffaele, Italy
Gene Editing of Memory Stem T Cells for Cancer Immunotherapy

Tuesday, February 13 | 8:00AM - 11:00AM
Cellular Therapies in Blood Malignancies and Beyond
Room: Quandary Peak

Speaker 6 of 7
Justin Eyquem, University of California, San Francisco, USA
Precision T Cell Engineering to Advance Adoptive T Cell Therapies

Tuesday, February 13 | 8:00AM - 11:00AM
Cellular Therapies in Blood Malignancies and Beyond
Room: Quandary Peak

Speaker 7 of 7
Charlotte Mousset, Radboudumc, Netherlands
Short Talk: Superior Multi-Functionality and Glycolytic Function of Tumor-Reactive CD8+ TSCM-Like T Cells by ex vivo Akt-Inhibition

Tuesday, February 13 | 8:00AM - 11:00AM
Engineered T Cells for Viruses
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 1 of 7
* Philip D. Greenberg, University of Washington, USA


Tuesday, February 13 | 8:00AM - 11:00AM
Engineered T Cells for Viruses
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 2 of 7
Catherine M. Bollard, Children’s National Health System, USA
Developing HIV-Specific T Cell Therapies: Lessons from EBV


Tuesday, February 13 | 8:00AM - 11:00AM
Engineered T Cells for Viruses
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 3 of 7
Paula M. Cannon, University of Southern California, Keck School of Medicine, USA
Shutting the Door on HIV by Engineering Hematopoietic Stem Cells


Tuesday, February 13 | 8:00AM - 11:00AM
Engineered T Cells for Viruses
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak


Coffee Break


Tuesday, February 13 | 8:00AM - 11:00AM
Engineered T Cells for Viruses
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 5 of 7
James L. Riley, University of Pennsylvania, USA
Engineering T Cells to Functionally Cure HIV-1 Infection


Tuesday, February 13 | 8:00AM - 11:00AM
Engineered T Cells for Viruses
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 6 of 7
Scott G. Kitchen, University of California, Los Angeles AIDS Institute, USA
Engineering Antiviral CAR T Cell Immunity through Hematopoietic Stem/Progenitor Cells


Tuesday, February 13 | 8:00AM - 11:00AM
Engineered T Cells for Viruses
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 7 of 7
Alok Vishnu Joglekar, California Institute of Technology, USA
Short Talk: Hematopoietic Stem/Progenitor Cells Engineered with T Cell Receptors for Immunotherapy for HIV Infection


Tuesday, February 13 | 11:00AM - 5:00PM
On Own for Lunch


Tuesday, February 13 | 11:00AM - 1:00PM
Poster Setup
Room: Colorado Rockies Ballroom


Tuesday, February 13 | 1:00PM - 10:00PM
Poster Viewing
Room: Colorado Rockies Ballroom


Tuesday, February 13 | 4:30PM - 5:00PM
Coffee Available
Room: Longs Peak Foyer


Tuesday, February 13 | 5:00PM - 7:00PM
Lymphocytes as Elements of the Tumor Microenvironment
Room: Quandary Peak

Speaker 1 of 5
* Katia Georgopoulos, Massachusetts General Hospital, USA

Tuesday, February 13 | 5:00PM - 7:00PM
Lymphocytes as Elements of the Tumor Microenvironment
Room: Quandary Peak

Speaker 2 of 5
David H. Raulet, University of California, Berkeley, USA
Natural Killer Cell Activation and Inhibition: Potential for Cancer Therapy

Tuesday, February 13 | 5:00PM - 7:00PM
Lymphocytes as Elements of the Tumor Microenvironment
Room: Quandary Peak

Speaker 3 of 5
Michael Khodadoust, Stanford University, USA
T Cell Recognition of Lymphoma Immunoglobulin

Tuesday, February 13 | 5:00PM - 7:00PM
Lymphocytes as Elements of the Tumor Microenvironment
Room: Quandary Peak

Speaker 4 of 5
Mikala Egeblad, Cold Spring Harbor Laboratory, USA
Visualization of the Switch from Immune Control to Immune Escape

Tuesday, February 13 | 5:00PM - 7:00PM
Lymphocytes as Elements of the Tumor Microenvironment
Room: Quandary Peak

Speaker 5 of 5
Annelise Snyder, University of Washington, USA
Short Talk: Anti-tumor Effects of Inflammatory Necroptosis Within the Tumor Microenvironment

Tuesday, February 13 | 5:00PM - 7:00PM
CAR/TCR in the Clinic for Cancer
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 1 of 5
* Jeffrey S. Miller, University of Minnesota, USA


Tuesday, February 13 | 5:00PM - 7:00PM
CAR/TCR in the Clinic for Cancer
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 2 of 5
Stephen J. Forman, City of Hope, USA
CAR T Cells for Treatment of Central Nervous System (CNS) Malignancy


Tuesday, February 13 | 5:00PM - 7:00PM
CAR/TCR in the Clinic for Cancer
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 3 of 5
Marcela V. Maus, Harvard Medical School, USA
CAR T Cells Multiple Myeloma and Glioblastoma


Tuesday, February 13 | 5:00PM - 7:00PM
CAR/TCR in the Clinic for Cancer
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 4 of 5
Saar I. Gill, University of Pennsylvania, USA
CAR T Cells for Acute Myelogenous Leukemia


Tuesday, February 13 | 5:00PM - 7:00PM
CAR/TCR in the Clinic for Cancer
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 5 of 5
Jenessa Barbara Smith, Poseida Therapeutics, USA
Short Talk: PSMA-Specific CAR T-Stem Cell Memory Therapy Eliminates Solid Tumor in Prostate Cancer Model


Tuesday, February 13 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Colorado Rockies Ballroom
No registration fees are used to fund alcohol served at this function.

Tuesday, February 13 | 7:30PM - 10:00PM
Poster Session 2
Room: Colorado Rockies Ballroom


Wednesday, February 14 | 7:00AM - 8:00AM
Breakfast
Room: Colorado Rockies Ballroom


Wednesday, February 14 | 8:00AM - 11:00AM
Emerging Technologies: Visualization and Dissection of the T
umor Microenvironment

Room: Quandary Peak

Speaker 1 of 6
* Mikala Egeblad, Cold Spring Harbor Laboratory, USA

Wednesday, February 14 | 8:00AM - 11:00AM
Emerging Technologies: Visualization and Dissection of the T
umor Microenvironment

Room: Quandary Peak

Speaker 2 of 6
Dana Pe'er, Memorial Sloan Kettering Cancer Center, USA
A Single Cell Approach to Understanding the Tumor Microenvironment

Wednesday, February 14 | 8:00AM - 11:00AM
Emerging Technologies: Visualization and Dissection of the T
umor Microenvironment

Room: Quandary Peak

Speaker 3 of 6
Matthew F. Krummel, University of California, San Francisco, USA
Imaging a World beyond Checkpoints: Innate Partners for Lymphocytes in Cancer


Wednesday, February 14 | 8:00AM - 11:00AM
Emerging Technologies: Visualization and Dissection of the T
umor Microenvironment

Room: Quandary Peak


Coffee Break

Wednesday, February 14 | 8:00AM - 11:00AM
Emerging Technologies: Visualization and Dissection of the T
umor Microenvironment

Room: Quandary Peak

Speaker 5 of 6
Jerome Galon, INSERM UMRS1138, Cordeliers Research Center, France
Immunoscore as a Stronger Predictor of Patient Survival in Colorectal Cancer

Wednesday, February 14 | 8:00AM - 11:00AM
Emerging Technologies: Visualization and Dissection of the T
umor Microenvironment

Room: Quandary Peak

Speaker 6 of 6
Michael Goldberg, Dana-Farber Cancer Institute, USA
Enhancing Cancer Immunotherapy through Immuno-engineering

Wednesday, February 14 | 8:00AM - 11:15AM
Tregs as Cellular Therapeutics
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 1 of 8
* James L. Riley, University of Pennsylvania, USA


Wednesday, February 14 | 8:00AM - 11:15AM
Tregs as Cellular Therapeutics
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 2 of 8
Bruce R. Blazar, University of Minnesota, USA
Vimentin Restrains Regulatory T-cell Suppression of Graft-versus-Host Disease


Wednesday, February 14 | 8:00AM - 11:15AM
Tregs as Cellular Therapeutics
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 3 of 8
Jeffrey A. Bluestone, University of California, San Francisco, USA
Manipulating Tregs to Control Tolerance in Autoimmunity and Cancer


Wednesday, February 14 | 8:00AM - 11:15AM
Tregs as Cellular Therapeutics
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak


Coffee Break


Wednesday, February 14 | 8:00AM - 11:15AM
Tregs as Cellular Therapeutics
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 5 of 8
Megan K. Levings, University of British Columbia, Canada
HLA-A2 Directed CAR Tregs


Wednesday, February 14 | 8:00AM - 11:15AM
Tregs as Cellular Therapeutics
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 6 of 8
David Klatzmann, Sorbonne University Medical School, France
IL-2 for Treg-Based Immunotherapies: In (and Out)


Wednesday, February 14 | 8:00AM - 11:15AM
Tregs as Cellular Therapeutics
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 7 of 8
Angela C. Boroughs, Massachusetts General Hospital/Harvard University, USA
Short Talk: 4-1BB Co-Stimulation Inhibits CAR Treg Suppressive Function


Wednesday, February 14 | 8:00AM - 11:15AM
Tregs as Cellular Therapeutics
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 8 of 8
Elmar Jaeckel, Hannover Medical School, Germany
Short Talk: Operational Tolerance in Allotransplantation by Use of Regulatory T Cells with a MHC-Specific Chimeric Antigen Receptor


Wednesday, February 14 | 11:15AM - 5:00PM
On Own for Lunch


Wednesday, February 14 | 2:30PM - 4:30PM
Workshop 2: Cell Engineering
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 1 of 9
* Martin Pule, University College London, UK


Wednesday, February 14 | 2:30PM - 4:30PM
Workshop 2: Cell Engineering
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 2 of 9
Zinaida Good, Stanford University, USA
Guiding T-Lymphocyte Differentiation in Cancer Immunotherapy Applications


Wednesday, February 14 | 2:30PM - 4:30PM
Workshop 2: Cell Engineering
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 3 of 9
Rachel C. Lynn, Lyell Immunopharma, USA
Disrupting the Balance: Engineering AP1 to Overcome CAR T Cell Exhaustion


Wednesday, February 14 | 2:30PM - 4:30PM
Workshop 2: Cell Engineering
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 4 of 9
Shannon K. Oda, Fred Hutchinson Cancer Research Center, USA
Cheating Death: A Fas-4-1BB Immunomodulatory Fusion Protein Obviates a Death Signal to Enhance T Cell Function and Adoptive Therapy Targeting Leukemia and Solid Tumors


Wednesday, February 14 | 2:30PM - 4:30PM
Workshop 2: Cell Engineering
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 5 of 9
William Lemieux, University of Montréal, Canada
Efficient Transduction of Nk Cells Method Resulting in a Robust and Sustained Transgene Expression for Immunotherapy


Wednesday, February 14 | 2:30PM - 4:30PM
Workshop 2: Cell Engineering
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 6 of 9
Masataka Suzuki, Baylor College of Medicine, USA
Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments Chimeric Antigen Receptor T-Cell against Metastatic Head and Neck Cancer


Wednesday, February 14 | 2:30PM - 4:30PM
Workshop 2: Cell Engineering
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 7 of 9
Tori Yamamoto, NCI, University of Pennsylvania, USA
Cell Intrinsic Fas Signaling Inhibition to Improve Therapeutic Efficacy of T Cells


Wednesday, February 14 | 2:30PM - 4:30PM
Workshop 2: Cell Engineering
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 8 of 9
Nicholas F. Kuhn, Memorial Sloan Kettering Cancer Center, USA
Design of a Systemic Antitumor Response with CD40L-modified CAR T Cells


Wednesday, February 14 | 2:30PM - 4:30PM
Workshop 2: Cell Engineering
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 9 of 9
Joy (Yushu) Xie, Massachusetts Institute of Technology, USA
Engineering Single Domain Antibody-Based Chimeric Antigen Receptor T Cells for Treatment of Solid Tumors


Wednesday, February 14 | 4:30PM - 5:00PM
Coffee Available
Room: Longs Peak Foyer


Wednesday, February 14 | 5:00PM - 7:00PM
Emerging Concepts in the Development of Tumor Vaccines
Room: Quandary Peak

Speaker 1 of 5
* Dimitris Skokos, Regeneron Pharmaceuticals, USA

Wednesday, February 14 | 5:00PM - 7:00PM
Emerging Concepts in the Development of Tumor Vaccines
Room: Quandary Peak

Speaker 2 of 5
Ugur Sahin, BioNTech AG, Germany
Systemic RNA Delivery, Dendritic Cell Vaccines and Implications for Cancer Immunotherapy

Wednesday, February 14 | 5:00PM - 7:00PM
Emerging Concepts in the Development of Tumor Vaccines
Room: Quandary Peak

Speaker 3 of 5
Cornelis J. M. Melief, Leiden University Medical Center & ISA Pharmaceuticals BV, Netherlands
Combination Immunotherapy of Cancers Caused by High-Risk HPV16

Wednesday, February 14 | 5:00PM - 7:00PM
Emerging Concepts in the Development of Tumor Vaccines
Room: Quandary Peak

Speaker 4 of 5
Johanna Olweus, University of Oslo, Norway
Selecting Immunogenic Targets for Cancer Immunotherapy

Wednesday, February 14 | 5:00PM - 7:00PM
Emerging Concepts in the Development of Tumor Vaccines
Room: Quandary Peak

Speaker 5 of 5
Samarth Hegde, Washington University School of Medicine, USA
Short Talk: Tumor Antigenicity Accelerates Early Pancreatic Adenocarcinoma Progression

Wednesday, February 14 | 5:00PM - 7:00PM
Beyond T Cells: HSC, T Progenitor and IPSCs I
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 1 of 4
* Juan Carlos Zúñiga-Pflücker, Sunnybrook Research Institute, Canada


Wednesday, February 14 | 5:00PM - 7:00PM
Beyond T Cells: HSC, T Progenitor and IPSCs I
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 2 of 4
Martin Pule, University College London, UK
New Designs in Synthetic T Cells


Wednesday, February 14 | 5:00PM - 7:00PM
Beyond T Cells: HSC, T Progenitor and IPSCs I
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 3 of 4
Jeffrey S. Miller, University of Minnesota, USA
Novel Ways to Activate and Target NK Cells to Treat Cancer


Wednesday, February 14 | 5:00PM - 7:00PM
Beyond T Cells: HSC, T Progenitor and IPSCs I
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 4 of 4
Linda T. Vo, University of California, San Francisco, USA
T Cell Engineering from Human Pluripotent Stem Cells


Wednesday, February 14 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Colorado Rockies Ballroom
No registration fees are used to fund alcohol served at this function.

Thursday, February 15 | 7:00AM - 8:00AM
Breakfast
Room: Colorado Rockies Ballroom


Thursday, February 15 | 8:00AM - 11:00AM
Combinatorial Treatments and their Effects on Lymphocyte Fun
ction in Cancer

Room: Quandary Peak

Speaker 1 of 7
* Ashley M. Laughney, Memorial Sloan Kettering Cancer Center, USA

Thursday, February 15 | 8:00AM - 11:00AM
Combinatorial Treatments and their Effects on Lymphocyte Fun
ction in Cancer

Room: Quandary Peak

Speaker 2 of 7
David G. DeNardo, Washington University Medical School, USA
The Pancreatic Tumor Microenvironment; Modulator of Tumor Progression and Response to Therapy

Thursday, February 15 | 8:00AM - 11:00AM
Combinatorial Treatments and their Effects on Lymphocyte Fun
ction in Cancer

Room: Quandary Peak

Speaker 3 of 7
Dimitris Skokos, Regeneron Pharmaceuticals, USA
T Cell Dysfunction and Combination Immunotherapy

Thursday, February 15 | 8:00AM - 11:00AM
Combinatorial Treatments and their Effects on Lymphocyte Fun
ction in Cancer

Room: Quandary Peak


Coffee Break

Thursday, February 15 | 8:00AM - 11:00AM
Combinatorial Treatments and their Effects on Lymphocyte Fun
ction in Cancer

Room: Quandary Peak

Speaker 5 of 7
Michael A. Curran, University of Texas MD Anderson Cancer Center, USA
Optimizing T Cell Frequency and Function via Checkpoint Antibody / Vaccine Combinations

Thursday, February 15 | 8:00AM - 11:00AM
Combinatorial Treatments and their Effects on Lymphocyte Fun
ction in Cancer

Room: Quandary Peak

Speaker 6 of 7
Sjoerd H. van der Burg, Leiden University Medical Center, Netherlands
Combination Treatments to Modulate the Microenvironment and Boost Tumor-Specific T Cells

Thursday, February 15 | 8:00AM - 11:00AM
Combinatorial Treatments and their Effects on Lymphocyte Fun
ction in Cancer

Room: Quandary Peak

Speaker 7 of 7
Yuliya Pylayeva-Gupta, University of North Carolina at Chapel Hill, USA
Short Talk: IL-35+ B Cells Establish Immunosuppressive Network in Pancreatic Ductal Adenocarcinoma

Thursday, February 15 | 8:00AM - 11:00AM
Beyond T Cells: HSC, T Progenitor and IPSCs II
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 1 of 7
* Bruce R. Blazar, University of Minnesota, USA


Thursday, February 15 | 8:00AM - 11:00AM
Beyond T Cells: HSC, T Progenitor and IPSCs II
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 2 of 7
Juan Carlos Zúñiga-Pflücker, Sunnybrook Research Institute, Canada
Generation of Human Progenitor T Cells from Stem Cells


Thursday, February 15 | 8:00AM - 11:00AM
Beyond T Cells: HSC, T Progenitor and IPSCs II
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 3 of 7
Sjoukje J.C. van der Stegen, Memorial Sloan Kettering Cancer Center, USA
Development of CD8alphabeta+ CAR T Cells from Human Pluripotent Stem Cells


Thursday, February 15 | 8:00AM - 11:00AM
Beyond T Cells: HSC, T Progenitor and IPSCs II
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak


Coffee Break


Thursday, February 15 | 8:00AM - 11:00AM
Beyond T Cells: HSC, T Progenitor and IPSCs II
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 5 of 7
Jakub Tolar, University of Minnesota, USA
Gene-Edited Stem Cells: From Cloning to Clinic


Thursday, February 15 | 8:00AM - 11:00AM
Beyond T Cells: HSC, T Progenitor and IPSCs II
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 6 of 7
Saar I. Gill, University of Pennsylvania, USA
Chimeric Antigen Receptor Macrophages for the Treatment of Solid Tumors


Thursday, February 15 | 8:00AM - 11:00AM
Beyond T Cells: HSC, T Progenitor and IPSCs II
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 7 of 7
Katelyn Masiuk, University of California, Los Angeles, USA
Short Talk: Hematopoietic Stem Cell Gene Therapy for IPEX Syndrome


Thursday, February 15 | 11:00AM - 5:00PM
On Own for Lunch


Thursday, February 15 | 4:30PM - 5:00PM
Coffee Available
Room: Longs Peak Foyer


Thursday, February 15 | 5:00PM - 6:45PM
Future Directions for Next-Generation Sequencing: Genomics,
Epigenetics and Immunogenomics

Room: Quandary Peak

Speaker 1 of 4
* Iannis Aifantis, New York University School of Medicine, USA

Thursday, February 15 | 5:00PM - 6:45PM
Future Directions for Next-Generation Sequencing: Genomics,
Epigenetics and Immunogenomics

Room: Quandary Peak

Speaker 2 of 4
Ashley M. Laughney, Memorial Sloan Kettering Cancer Center, USA
Dissecting Tumor Cell Plasticity and Population Interactions Supporting Metastasis using Single Cell Genomics

Thursday, February 15 | 5:00PM - 6:45PM
Future Directions for Next-Generation Sequencing: Genomics,
Epigenetics and Immunogenomics

Room: Quandary Peak

Speaker 3 of 4
Mickey Atwal, Cold Spring Harbor Laboratory, USA
High-Throughput Profiling of T Cell Receptor Sequences in Cancer Immunotherapy

Thursday, February 15 | 5:00PM - 6:45PM
Future Directions for Next-Generation Sequencing: Genomics,
Epigenetics and Immunogenomics

Room: Quandary Peak

Speaker 4 of 4
Rahul Satija, New York Genome Center, USA
Integrated Analysis of Single Cell Data across Modalities, Technologies and Species

Thursday, February 15 | 5:00PM - 6:45PM
Intersection of Genetic Editing and Cellular Therapy
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 1 of 4
* Marcela V. Maus, Harvard Medical School, USA


Thursday, February 15 | 5:00PM - 6:45PM
Intersection of Genetic Editing and Cellular Therapy
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 2 of 4
Alex Marson, University of California, San Francisco, USA
Reprogramming Human T Cell Circuitry


Thursday, February 15 | 5:00PM - 6:45PM
Intersection of Genetic Editing and Cellular Therapy
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 3 of 4
Andrew M. Scharenberg, Casebia Therapeutics, USA
Engineering Regulatory T Cells for Inflammatory Disorders


Thursday, February 15 | 5:00PM - 6:45PM
Intersection of Genetic Editing and Cellular Therapy
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak

Speaker 4 of 4
Carl H. June, University of Pennsylvania, USA
Adoptive Transfer with Genetically Edited T Cells


Thursday, February 15 | 6:45PM - 7:00PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Room: Quandary Peak


Thursday, February 15 | 6:45PM - 7:00PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
This session is from Emerging Cellular Therapies
Room: Grays/Longs Peak


Thursday, February 15 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Colorado Rockies Ballroom
No registration fees are used to fund alcohol served at this function.

Thursday, February 15 | 8:00PM - 11:00PM
Entertainment
Room: Colorado Rockies Ballroom
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Thursday, February 15 | 8:00PM - 11:00PM
Cash Bar
Room: Colorado Rockies Ballroom


Friday, February 16 | 10:24AM - 10:24AM
Departure


*Session Chair
†Invited, not yet responded.